



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	09/995,225
Filing Date	November 26, 2001
First Named Inventor	Ruoping Chen et al.
Art Unit	1646
Examiner Name	Nirmal Singh Basi
Attorney Docket Number	21.US18.CIP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
NH	CO	ELBLE, RODGER, J., "Animal Models of Action Tremor," <i>Movement Disorders</i> , 13(3):35-39, (1998)	
	CP	JELJELI, M., ET AL., "Effects of centrolateral or medial thalamic lesions on motor coordination and spatial orientation in rats," <i>Neuroscience Research</i> , 38:155-164, (2000)	
	CQ	KARPE, F. and FRAYN, K.N., "The nicotinic acid receptor—a new mechanism for an old drug," <i>The Lancet</i> , 363:1892-1894, (June, 2004)	
	CR	McNAMARA, J.O. "Drugs Effective in the Therapy of the Epilepsies," <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i> , Ninth Edition, Chapter 20, pp. 461-486, 1996	
	CS	PORTAS, C.M., ET AL., "A Specific Role for the Thalamus in Mediating the Interaction of Attention and Arousal in Humans," <i>The Journal of Neuroscience</i> , 18(21):8979-8989, (November, 1998)	
	CT	PROBST, WILLIAM C., ET AL., "Sequence Aligment of the G-Protein Coupled Receptor Superfamily," <i>DNA and Cell Biology</i> , 11(1):1-20, (1992)	
	CU	SONNHAMMER, ERIK L.L., ET AL., "A Hidden Markov Model for Predicting Transmembrane Helices in Protein Sequences," <i>Proc. Int. Conf. Intell. Syst. Mol. Biol.</i> , 6:175-82, (1998)	
	CV	ZADINA, J.E., ET AL., "Endomorphins: Novel Endogenous $\mu$ -Opiate Receptor Agonists in Regions of High $\mu$ -Opiate Receptor Density," <i>Annals New York Academy of Sciences</i> , 897:136-144, (1999)	

Examiner Signature	N. Singh / R	Date Considered	4/25/06
-----------------------	--------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\*\*A COPY OF THIS REFERENCE WILL NOT BE FORWARDED TO THE U.S. PATENT AND TRADEMARK OFFICE SINCE IT IS BELIEVED TO BE TOO VOLUMINOUS AND EASILY OBTAINABLE BY THE EXAMINER.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet

1

C

1

Attorney Docket Number

**Complete If Known**

**Application Number**

09/995.225

**Filing Date**

November 26, 2001

**First Named Inventor**

**Ruoping Chen**

**Art Unit**

1646

**Examiner Name**

**Nirmal Singh Basi**

Attorney Docket Number

21.US18.CIP (133051)

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
NSB ↓	CI	WO 2004/074841 A2	09-02-2004	Regeneron Pharm.		
	CJ	WO 2001/94582 A1 (w/Eng. Abstract)	12-13-2001	Takeda Chem. Indus.		
	CK	WO 2002/077001 A2	10-03-2002	Tularik Inc.		
	CL	WO 2003/027142 A1 (w/Eng. Abstract)	04-03-2003	Yamanouchi Pharm.		
	CM	WO 2002/48358 A2	06-20-2002	Bayer Aktiengesellschaft		
	CN	WO 2001/70978 A2	09-27-2001	Curagen Corp.		

**Examiner  
Signature**

Date Considered

4/25/24

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**